HES can provide the kind of real-world evidence that some life sciences companies have a great deal of difficulty in ...

Eli Lilly has raised the stakes in the obesity market with midstage data for an amylin-targeting drug, eloralintide, that ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

The new data from the OASIS 4 trial of Novo Nordisk's 25 mg oral formulation of semaglutide included an indirect comparison ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

The merger of two pioneers of psychedelic medicines has completed with the creation of AtaiBeckley, a company with a pipeline ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

"The UK's inability to retain economic benefits of its R&D is a fatal flaw to any growth strategy," according to the document ...

The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...

That research led to the FDA granting compassionate use of the doxecitine and doxribtimine treatment in Arturito Estopinan, ...